Frustrated phagocytosis leading to malignant pleural mesothelioma (Homo sapiens)
From WikiPathways
Description
Adverse Outcome Pathway for malignant pleural mesothelioma, known to be initiated by asbestos and carbon nanotubes. This molecular AOP is based on https://aopwiki.org/aops/409
Quality Tags
Ontology Terms
Bibliography
- Akio Kuroda; ''Recent progress and perspectives on the mechanisms underlying Asbestos toxicity''; , 2021 PubMed Europe PMC Scholia
- Gupta SS, Singh KP, Gupta S, Dusinska M, Rahman Q; ''Do Carbon Nanotubes and Asbestos Fibers Exhibit Common Toxicity Mechanisms?''; Nanomaterials (Basel), 2022 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
View all... |
Name | Type | Database reference | Comment |
---|---|---|---|
Activating invasion and metastasis | |||
Apoptosis pathway mutations | Pathway | WP1772 (WikiPathways) | |
Avoiding immune destruction | |||
Cell Cycle | Pathway | WP179 (WikiPathways) | |
Cell cycle checkpoints | Pathway | WP45 (WikiPathways) | |
DNA damage response | Pathway | WP707 (WikiPathways) | |
DNA repair pathways | Pathway | WP4946 (WikiPathways) | |
Damaged BER pathway | Pathway | WP4752 (WikiPathways) | |
Damaged NER pathway | Pathway | WP4753 (WikiPathways) | |
Deregulating cellular energetics | |||
Evading growth suppressors | |||
Frustrated phagocytosis | Key Event | 1668 (AOP-Wiki KE) | |
Genomic instability | Key Event | 1896 (AOP-Wiki KE) | |
HoC: Sustaining proliferative signalling | Pathway | WP5475 (WikiPathways) | |
Immune infiltration | Pathway | WP5285 (WikiPathways) | |
Increased DNA damage and mutation | Key Event | 1669 (AOP-Wiki KE) | |
Increased reactive oxygen species | Key Event | 1115 (AOP-Wiki KE) | |
Increased recruitment of inflammatory cells | Key Event | 1497 (AOP-Wiki KE) | |
Increased secretion of proinflammatory mediators | Key Event | 1496 (AOP-Wiki KE) | |
Inducing angiogenesis | |||
Mesothelial cell proliferation | Key Event | 870 (AOP-Wiki KE) | |
Mesothelioma | Key Event | 1090 (AOP-Wiki KE) | |
Metastasis and epithelial-to-mesenchymal transition | Pathway | WP5469 (WikiPathways) | |
NRF2 pathway | Pathway | WP2884 (WikiPathways) | |
Neovascularization processes | Pathway | WP4331 (WikiPathways) | |
Nonmutational epigenetic reprogramming | |||
Nonmutational epigenetic reprogramming | Pathway | WP5483 (WikiPathways) | |
Overview of proinflammatory and profibrotic mediators | Pathway | WP5095 (WikiPathways) | |
Oxidative damage response | Pathway | WP3941 (WikiPathways) | |
Resisting cell death | |||
Sustaining proliferative signaling | |||
T cell modulation | Pathway | WP5078 (WikiPathways) | |
TCA Cycle Nutrient use in cancer | Pathway | WP2868 (WikiPathways) | |
Tumor suppressor gene mutations | Pathway | WP1742 (WikiPathways) |
Annotated Interactions
No annotated interactions